Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
30 oct. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
Highlights: Participant screening closed for ATH434-201 Phase 2 studyIndependent Data Monitoring Committee recommended the ATH434-201 Phase 2 study continue as plannedReceived A$4.74M cash refund...
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
31 août 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- Presentations Convey Novel Approach for Improving Diagnostic Accuracy and Tracking Disease Severity in MSA - - Data Presented at the International Congress of Parkinson’s Disease and Movement...
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
23 août 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
22 août 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
15 août 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
31 juil. 2023 07h52 HE
|
ALTERITY THERAPEUTICS LIMITED
Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with Multiple System Atrophy (MSA)ATH434-201 Phase 2 Data...
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
26 juil. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia and SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Alterity...
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
21 juin 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, June 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
30 mai 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434 now being evaluated in early and more advanced Multiple System Atrophy - - New trial expected to generate data before ongoing Phase 2 trial - MELBOURNE, Australia and SAN FRANCISCO, May...
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
19 mai 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, May 19, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...